The healthcare industry is entering the new year with a strong momentum, backed by increased transparency surrounding government healthcare policies and a surge of investor interest. The sector’s future earnings prospects are on the rise, spurred by a robust innovation pipeline and the emergence of new market segments. Despite this, healthcare stocks continue to trade at a discount relative to the global market, creating a re-evaluation underway that is accelerating. At present levels, there are still appealing opportunities for increasing exposure to the healthcare sector.
The sector’s momentum is being bolstered by five key developments:
Firstly, policy clarity is attracting investors back to the sector. The pricing agreement reached between the US administration and Pfizer in September, and subsequent agreements with Eli Lilly and Novo Nordisk in November, marked a significant turning point. These developments have resulted in a predictable framework for drug pricing and reimbursement policies, thereby reducing uncertainty and improving planning visibility. Reaction from investors was swift, with healthcare emerging as one of the strongest global stock market performers this quarter, attracting an additional $8 billion in capital to healthcare ETFs worldwide in just three months.
Secondly, a re-evaluation process has begun, with further potential for catch-up. Healthcare valuations are moving back towards historical averages, but the sector is still valued approximately 13% lower than global stocks. The future looks bright for healthcare companies, with average profit growth predictions for biopharmaceuticals and life science tools between 2024 and 2027 standing at approximately 15%, more than double the historical growth rate of about 7% per year.
Thirdly, the biopharma sector is set to benefit from formidable growth drivers and high M&A capacity. Looking ahead to 2026, this sector stands to gain from various structural trends such as new oncology treatment classifications, advances in obesity and diabetes treatments, and therapeutic innovations in cardiovascular care.
Fourthly, the medical technology sector continues to be a key growth driver, spurred by high demand in established markets and the emergence of new billion-dollar niches. Markets such as robot-assisted surgical systems, glucose monitoring devices, and structural heart disease treatment continue to register double-digit growth rates.
Lastly, emerging markets are boosting their innovation capabilities and market clout. These markets are steadily transforming into innovation powerhouses in their own right. China, for instance, is transitioning from an out-licensing partner to a global pharmaceutical player, while India’s rapidly growing middle class and substantial government healthcare infrastructure spending stand out as growth engines.
Entering 2026, the healthcare sector is backed by strong structural growth drivers and improved earnings visibility. Innovation continues to be key, supported by robust pipelines, new therapy platforms, and tech-enhanced solutions. However, the sector’s performance disparity, as measured by the MSCI World Healthcare Index, is also noteworthy, with a performance gap of +72% and -38% between the best and worst-performing stocks in the first half of 2025.
After a recent period of policy uncertainty, the healthcare sector is back in its historical position of innovation, growth, and high operational visibility, a position from which it has consistently delivered tangible value.
What has attracted investors back to the healthcare sector?
Investors are being drawn back to the healthcare sector due to increased policy clarity, including agreements on drug pricing and reimbursement policies between the US administration and pharmaceutical companies.
What are some key growth drivers for the biopharma sector looking ahead to 2026?
Key growth drivers for the biopharma sector include new classifications of oncology treatments, advancements in obesity and diabetes treatments, and therapeutic innovations in cardiovascular care.
How are emerging markets contributing to the growth of the healthcare sector?
Emerging markets like China and India are increasingly becoming innovation powerhouses in their own right. China is transitioning from an out-licensing partner to a global pharmaceutical player, while India’s growing middle class and substantial government spending on healthcare infrastructure are key growth drivers.
